Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.
An abstract is unavailable.
tuesday, february 25 *-Short talk from proffered abstract CONTINENTAL BREAKFAST 7-8 a.m. Major Symposia 4-5 8-9:30 a.m. Major Symposium 4: Neoadjuvant Immunotherapy Session Chair: Christian…
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when…
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
